SUMMARY Twenty-eight children with ,B-thalassaemia major aged between 11 and 48 months were given intensive transfusions. Serum iron, transferrin saturation, serum ferritin, non-transferrin iron, and subcutaneous desferrioxamine-induced urinary iron excretion were measured. The results showed that even children with a limited number of transfusions had severe iron overload as indicated, in particular, by the raised serum ferritin levels and the high excretion rates after subcutaneous infusion of desferrioxamine. The desferrioxamine test was useful, even in very young children, in assessing response to chelation therapy thus enabling such treatment to be started early to prevent harm from iron overload.
Severe iron overload develops progressively in patients with transfusion-dependent homozygous r-thalassaemia, so that there is a need for continuous chelation therapy. The recent use of subcutaneous desferrioxamine infusion now enables chelation therapy to be started early even though its effectiveness in preventing toxic iron accumulation in 13 -thalassaemia major children still has to be proved.1-7
The purpose of this work was to study serum iron, transferrin saturation, serum ferritin, the non-specific iron fraction,8 and urinary iron excretion in polytransfused patients with Pthalassaemia major, aged between 11 and 48 months, before they were started on chelation therapy, in order to assess at what age iron overload and early signs of iron toxicity develop and how soon chelation therapy should be started.
Patients
Twenty-eight children with ,-thalassaemia major, aged between 11 and 48 months, not yet given chelation therapy, were studied. Each was given regular intensive transfusion, starting at age 6-12 months. The annual mean Hb level was higher than 12.9 g/dl (Table 1) . None had been splenectomised. Beta-thalassaemia major was diagnosed by routine tests, by the degree of anaemia before blood transfusion, and by the parents' history. On the hypothesis that the patients had vitamin C deficiency ( Unbound iron was measured in duplicate serum samples using the method of Hershko et al. 8 All sera were obtained from patients before being given iron chelation therapy for 3 days. Briefly, 1 ml of serum was mixed with 0-5 ml of pH 7.45 buffer containing 5 mmol/l tris and 0*16 mol/l sodium chloride and 0.5 ml 0-01 mol/l EDTA, pH 7*5. The mixture was incubated at room temperature for 10 minutes.
The solution was then placed in a CF 25 Amicon filter cone (Amicon Corporation, Lexington, Massachussetts) and centiifuged at 400 x g for 20 min. The CF 25 Amicon filter cones retain 95 % of molecules with molecular weight greater than 25 000. About 1 ml of filtrate was obtained from each sample. Filtrate iron concentration was measured by atomic absorption spectroscopy.
Before use, the filters were soaked in EDTA for 2 hours in order to remove any iron contamination. Urinary iron excretion was evaluated by atomic absorption spectroscopy too. Red cells indices were determined in a Coulter electronic cell counter.
Osmotic fragility was measured by adding hypotonic saline buffered to pH 7.4 and haemolysis was read photoelectrically.
Hb A2 was quantitated by DEAE-cellulose chromatographyll and Hb F by alkali denaturation.'2 Statistical methods. The coefficient correlation (r) between two independent variables was calculated.
Results
The details of all the patients, their ages, their ages at the first blood transfusion, the total amount of blood transfused, and the levels of iron at the time of the study are shown in Table 2 .
Mean values for serum iron, transferrin saturation, serum ferritin, and urinary iron excretion are shown in Table 3 . All levels were high, even in the youngest group of children. Desferrioxamine-induced urinary iron excretion after a dose of 20 mg/kg resulted in high levels only in children between 37 and 48 months of age, but after a dose of 40 mg/kg the levels were very high in all children. There was no correlation between serum ferritin and the age of the patients. There was a weak correlation between desferrioxamine-induced urinary iron excretion (20 mg/kg) and the age of patients (P<0-05), but not after a dose of 40 mg/kg. Early iron overload in beta-thalassaemia major: when to start chelation theropy? 931 There was a significant correlation between the amount of blood transfused and the serum ferritin level (P<0.01) (Fig. 1) and between the amount of blood transfused and desferrioxamine-induced urinary iron excretion for both doses (P<0* 01) (Fig. 2) . A highly significant correlation between serum ferritin and 40 mg/kg desferrioxamineinduced urinary iron excretion rate (P<0*01) was observed, but not after 20 mg/kg (Fig. 3) .
Non-transferrin iron was detected in 11 of the 27 patients, being present in those in whom the transferrins were completely iron saturated ( Table 4 ). The non-specific iron concentrations were in the range of 9 and 28 sug/dl.
There was no correlation between non-specific iron and either serum ferritin or desferrioxamineinduced iron excretion.
Discussion
Our findings show that there can be severe iron overload in children younger than 4 years old. The intensive transfusion regimens to which the children were subjected led us to assume that the major endogenous factor influencing iron absorption, erythropoiesis, is minimal in such young children, so that roughly the entire iron load could be attributed to the blood received.13 This is confirmed by the significant correlation between serum ferritin, which reflects iron stored, and the amount of blood mg/day Desferrioxamine 20mg/kg 151 C12. The presence of non-transferrin iron in the sera of these patients confirms that iron overload and iron toxicity develop very early in children with P-thalassaemia major. The lack of correlation between non-transferrin iron and either serum ferritin or urinary iron excretion may be due to the fact that there were few patients studied or that the iron overload was at an early stage.
Our findings show that p-thalassaemia major children, even those younger than 2 years, can have a severe iron overload and that regular subcutaneous infusion of desferrioxamine could greatly improve survival and should be started as soon as possiblethat is from about the 3rd transfusion-according to the response of the patient to the desferrioxamine test performed with both doses (20 and 40 mg/kg a day). 
